SAN FRANCISCO, Oct. 28, 2016 /PRNewswire/ -- Nektar Therapeutics
(Nasdaq: NKTR) today announced five data presentations will be
delivered at the upcoming Society for Immunotherapy of Cancer
(SITC) Annual Meeting, which will be held November 9-13, 2016 at the Gaylord National Hotel
and Convention Center in National Harbor, Maryland. Investigators and researchers will
present new clinical and preclinical data on NKTR-214, the
Company's immuno-stimulatory CD122-biased agonist, as well as
preclinical data on NKTR-255, the Company's IL-15 therapeutic
candidate.
Details of the oral clinical data presentation are as
follows:
Title: A CD122-biased agonist increases CD8+T Cells and
natural killer cells in the tumor microenvironment; making cold
tumors hot with NKTR-214
Presenter: Dr. Adi Diab,
Assistant Professor, Department of Melanoma Medical Oncology,
Division of Cancer Medicine, The University of
Texas MD Anderson Cancer Center, Houston, Texas
Session: New Cancer Immunotherapy Agents in Development
Date: Wednesday, November 9,
2016, 11:10 a.m. –
12:20 p.m. Eastern Time
Details of the poster clinical data presentation are as
follows:
Poster 387: A CD122-biased agonist increases CD8+T Cells
and natural killer cells in the tumor microenvironment; making cold
tumors hot with NKTR-214
Session: Tumor Microenvironment
Date: Friday, November 11,
2016, 12:15 – 1:30 p.m. and
6:15 – 7:30 p.m. Eastern Time
Details of the poster preclinical data presentations are as
follows:
Poster 343: Anti-tumor activity of NKTR-214; a
CD122-biased agonist that promotes immune cell activation in the
tumor microenvironment and lymphoid tissues
Session: Promoting and Measuring Anti-Tumor Activity
Date: Friday, November 11,
2016, 12:15 – 1:30 p.m. and
6:15 – 7:30 p.m. Eastern Time
Poster 359: NKTR-214, an engineered cytokine, synergizes
and improves efficacy of anti-cancer vaccination in the treatment
of established murine melanoma tumors
Session: Therapeutic Cancer Vaccines
Date: Friday, November 11,
2016, 12:15 – 1:30 p.m. and
6:15 – 7:30 p.m. Eastern Time
Poster 342: NKTR-255: an IL-15-based therapeutic with
optimized biological activity and anti-tumor efficacy
Session: Promoting and Measuring Anti-Tumor Activity
Date: Saturday, November 12,
2016, 11:45 a.m. –
1:00 p.m. and 6:45 – 8:00 p.m. Eastern Time
About Nektar
Nektar Therapeutics has a robust
R&D pipeline and portfolio of approved partnered medicines in
oncology, pain, immunology and other therapeutic areas. In the area
of oncology, Nektar is developing NKTR-214, an
immuno-stimulatory CD122-biased agonist that is in Phase 1/2
clinical development for patients with solid tumors. ONZEALD™
(etirinotecan pegol), a long-acting topoisomerase I inhibitor, is
being developed for patients with advanced breast cancer and brain
metastases and is partnered with Daiichi Sankyo in Europe. In
the area of pain, Nektar has an exclusive worldwide
license agreement with AstraZeneca for MOVANTIK™ (naloxegol), the
first FDA-approved once-daily oral peripherally-acting
mu-opioid receptor antagonist (PAMORA) medication for the treatment
of opioid-induced constipation (OIC), in adult patients with
chronic, non-cancer pain. The product is also approved in
the European Union as MOVENTIG® (naloxegol) and is
indicated for adult patients with OIC who have had an inadequate
response to laxatives. The AstraZeneca agreement also includes
NKTR-119, an earlier stage development program that is a
co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly owned
mu-opioid analgesic molecule for chronic pain conditions, is in
Phase 3 development. In hemophilia, Nektar has a
collaboration agreement with Baxalta for ADYNOVATE™ [Antihemophilic
Factor (Recombinant)], a longer-acting PEGylated Factor VIII
therapeutic approved in the U.S. and Japan for
patients over 12 with hemophilia A. In anti-infectives, the company
has two collaborations with Bayer Healthcare, Cipro Inhale in
Phase 3 for non-cystic fibrosis bronchiectasis and Amikacin Inhale
in Phase 3 for patients with Gram-negative pneumonia.
Nektar's technology has enabled nine approved products in
the U.S. or Europe through partnerships with
leading biopharmaceutical companies, including AstraZeneca's
MOVANTIK™, Baxalta's ADYNOVATE™, UCB's Cimzia® for Crohn's disease
and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and
Amgen's Neulasta® for neutropenia.
Nektar is headquartered in San
Francisco, California, with additional operations
in Huntsville, Alabama and Hyderabad, India.
Further information about the company and its drug development
programs and capabilities may be found online
at http://www.nektar.com.
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark
of the AstraZeneca group of companies. ADYNOVATE™ is a
trademark of Baxalta Inc.
ONZEALD™ is a trademark of Nektar Therapeutics.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains
forward-looking statements which can be identified by words such
as: "anticipate," "intend," "plan," "expect," "believe," "should,"
"may," "will" and similar references to future periods. Examples of
forward-looking statements include, among others, statements we
make regarding the therapeutic potential of NKTR-214 and NKTR-255,
and the potential of our technology and drug candidates in our
research and development pipeline. Forward-looking statements
are neither historical facts nor assurances of future performance.
Instead, they are based only on our current beliefs, expectations
and assumptions regarding the future of our business, future plans
and strategies, anticipated events and trends, the economy and
other future conditions. Because forward-looking statements relate
to the future, they are subject to inherent uncertainties, risks
and changes in circumstances that are difficult to predict and many
of which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements. Important factors that could cause our actual results
to differ materially from those indicated in the forward-looking
statements include, among others: (i) NKTR-214 is in early-stage
clinical development and there are substantial risks that can
unexpectedly occur for numerous reasons including negative safety
and efficacy findings in the ongoing Phase 1 clinical study
notwithstanding positive findings in preclinical studies; (ii) our
drug candidates, including NKTR-214 and NKTR-255, are in various
stages of development and the risk of failure is high and can
unexpectedly occur at any stage prior to regulatory approval for
numerous reasons including negative safety and efficacy findings
even after positive findings in previous preclinical and clinical
studies; (iii) the timing of the commencement or end of clinical
trials and the availability of clinical data may be delayed or
unsuccessful due to regulatory delays, slower than anticipated
patient enrollment, manufacturing challenges, changing standards of
care, evolving regulatory requirements, clinical trial design,
clinical outcomes, competitive factors, or delay or failure in
ultimately obtaining regulatory approval in one or more important
markets; (iv) scientific discovery of new medical breakthroughs is
an inherently uncertain process and the future success of applying
our technology platform to potential new drug candidates (such as
NKTR-214 and NKTR-255) is therefore highly uncertain and
unpredictable and one or more research and development programs
could fail; (v) patents may not issue from our patent applications
for our drug candidates including NKTR-214 and NKTR-255, patents
that have issued may not be enforceable, or additional intellectual
property licenses from third parties may be required; and (vi)
certain other important risks and uncertainties set forth in our
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on August 4, 2016. Any
forward-looking statement made by us in this press release is based
only on information currently available to us and speaks only as of
the date on which it is made. We undertake no obligation to update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contact:
For Investors:
Jennifer Ruddock of Nektar
Therapeutics
415-482-5585
Jodi Sievers of Nektar
Therapeutics
415-482-5593
For Media:
Dan Budwick of Pure Communications,
Inc.
973-271-6085
dan@purecommunicationsinc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-announces-upcoming-presentations-at-the-2016-society-for-immunotherapy-of-cancer-annual-meeting-300353357.html
SOURCE Nektar Therapeutics